ArticleiMeta2025
Profiling chimeric RNA in prostate cancer in Chinese cohorts reveals similarities and differences compared to Western populations.
Article in iMeta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- A Unique Chimeric RNA: ERCC1-iASPP Drives Benzo[a]pyrene-Induced Lung Carcinogenesis via Dual Coding and Non-Coding Mechanisms.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Neuroendocrine prostate cancer (NEPC)-associatedCancer pathogenesis and therapy · 2026Article
- ABRAXAS1-HELQ is a candidate class-matched reference chimeric RNA and contributes to prostate cell motility through MCOLN2.Frontiers in oncology · 2026Article
- Ribosome RNA Extraction and RNase R Treatment.Methods in molecular biology (Clifton, N.J.) · 2026Article
- A Novel C19orf47-AKT2 Chimeric RNA Generated by Cis-Splicing of Adjacent Genes Is Associated With Glioblastoma Prognosis.Annals of clinical and translational neurology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Chimeric RNAs from chromosomal rearrangements have long been validated as cancer markers and therapeutic targets for many years. Recently, trans-splicing and cis-splicing between adjacent genes are also shown to generate chimeric RNAs. They influence tumor progression by coding fusion proteins, acting as long noncoding or circular RNAs, or altering parental gene expression. Here, we analyzed chimeric RNAs from The Cancer Genome Atlas and Chinese Prostate Cancer Genome and Epigenome Atlas, identifying similarities and differences between Western and Chinese prostate cancer (PCa) cohorts. We confirmed distinct chimeric RNA expression patterns among cancer epithelial cells, cancer-associated fibroblasts, tumor-associated macrophages, and T cells. We unraveled how these chimeras impact tumor cell growth, stromal cell transformation, and intercellular communication within the microenvironment. This comprehensive study establishes a chimeric transcriptome atlas for Chinese PCa patients, highlights population-specific disparities, and presents validated chimeric RNAs with diagnostic, prognostic, and therapeutic potential.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.